{"id":"NCT01777282","sponsor":"GlaxoSmithKline","briefTitle":"A Study to Determine the Long Term Safety and Efficacy of Albiglutide in Combination With Oral Monotherapy Antihyperglycemic Medications in Japanese Patients With Type 2 Diabetes Mellitus","officialTitle":"A 52-Week, Open-Label, Multicenter Study to Determine the Long Term Safety and Efficacy of Albiglutide in Combination With Monotherapy of Oral Antihyperglycemic Medications in Japanese Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-02-23","primaryCompletion":"2015-01-27","completion":"2015-01-27","firstPosted":"2013-01-28","resultsPosted":"2015-10-14","lastUpdate":"2017-05-03"},"enrollment":374,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Albiglutide","otherNames":[]},{"type":"DRUG","name":"Sulfonylurea","otherNames":[]},{"type":"DRUG","name":"Biguanide","otherNames":[]},{"type":"DRUG","name":"Glinide","otherNames":[]},{"type":"DRUG","name":"Thiazolidinedione","otherNames":[]},{"type":"DRUG","name":"Alpha-glucosidase inhibitor","otherNames":[]}],"arms":[{"label":"Albiglutide + Sulfonylurea","type":"ACTIVE_COMPARATOR"},{"label":"Albiglutide + Biguanide","type":"ACTIVE_COMPARATOR"},{"label":"Albiglutide + Glinide","type":"ACTIVE_COMPARATOR"},{"label":"Albiglutide + Thiazolidinedione","type":"ACTIVE_COMPARATOR"},{"label":"Albiglutide + Alpha-glucosidase inhibitor","type":"ACTIVE_COMPARATOR"}],"summary":"This study is designed to examine the long term safety and efficacy of weekly subcutaneously injected albiglutide in combination with a single oral antidiabetic drug for 52 weeks in Japanese subjects with type 2 diabetes mellitus.","primaryOutcome":{"measure":"Number of Participants With Any Adverse Event (AE) or Any Serious Adverse Event (SAE)","timeFrame":"From Baseline through Week 52","effectByArm":[{"arm":"Albiglutide Plus (+) Background OAD (Sulfonylurea)","deltaMin":97,"sd":null},{"arm":"Albiglutide Plus (+) Background OAD (Biguanide)","deltaMin":47,"sd":null},{"arm":"Albiglutide Plus (+) Background OAD (Glinide)","deltaMin":58,"sd":null},{"arm":"Albiglutide Plus (+) Background OAD (Thiazolidinedione)","deltaMin":49,"sd":null},{"arm":"Albiglutide Plus (+) Background OAD (Î±-Glucosidase Inhibitor)","deltaMin":43,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":6},"locations":{"siteCount":49,"countries":["Japan"]},"refs":{"pmids":["27852119"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":120},"commonTop":["Nasopharyngitis","Constipation","Hypoglycaemia","Diabetic retinopathy","Bronchitis"]}}